EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO

Henry J Kaminski, Carlo Antozzi iD, Ali A Habib iD, Robert M Pascuzzi, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Antoine Regnault, Asha Hareendran, Fiona Grimson, Thaïs Tarancón, Vera Bril iD und 1 weitere

European Journal of Neurology · 2025-08 · 32 (8)

DOI: 10.1111/ene.70231 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 04.08.2025. Verfasst von Henry J Kaminski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis, Patient Reported Outcome Measures, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the Phase 3 MycarinG study (NCT03971422), rozanolixizumab improved myasthenia gravis (MG)‐specific outcomes versus placebo in patients with generalised MG, including those measured by the five independent MG Symptoms patient‐reported outcome (PRO) scales: Muscle Weakness Fatigability (MWF), Physical Fatigue (PF) and Bulbar Muscle Weakness (BMW) as secondary endpoints and Ocular Muscle Weakness and Respiratory Muscle Weakness (exploratory endpoints). This research aimed to provide further insights into these improvements.

Methods

Post hoc analyses evaluated correlation (Pearson coefficient) between MG Symptoms PRO and subdomain scores of MG Activities of Daily Living (MG‐ADL) and Quantitative MG (QMG) at baseline. Proportions of responders reaching clinically meaningful thresholds and analyses at the item level (observed mean change and Rasch modelling of predicted change from baseline) are reported for MWF, PF, and BMW with rozanolixizumab versus placebo at Day 43.

Results

Correlation coefficients between MG Symptoms PRO and MG‐ADL were strong (≥ 0.7) for ocular and bulbar scores and moderate (0.5 to < 0.7) for other scores. Correlations with clinician‐assessed QMG scores were generally weak (< 0.5). For MWF, PF, and BMW, greater proportions of responders were observed with rozanolixizumab 7 mg/kg (46.9%, 31.3% and 26.6%, respectively) or 10 mg/kg (56.5%, 48.4% and 32.3%) versus placebo (28.1%, 26.6% and 10.9%). Item‐level analyses demonstrated rozanolixizumab benefit at a symptom‐specific level.

Discussion

MG Symptoms PRO scales correlate well with concepts in MG‐ADL while assessing additional concepts, such as PF and MWF. Results from the MG Symptoms PRO in MycarinG reflected improvements from baseline in patient‐relevant symptoms, including fatigue, with rozanolixizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisPatient Reported Outcome MeasuresAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAdultDouble-Blind MethodAgedActivities of Daily LivingTreatment OutcomeMuscle Weakness

Stichwörter der Autor:innen

clinical trialmyasthenia gravispatient‐reported outcome measurepatient‐reported outcomesphase 3rozanolixizumab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, District of Columbia, USA.
  • Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
  • MDA ALS & Neuromuscular Center, Department of Neurology, University of California Irvine, Orange, California, USA.
  • Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana, USA.
  • Université Côte d'Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France.
  • Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.

ORCID-Profile: Carlo Antozzi, Ali A Habib, Vera Bril

Förderung

  • UCB

Zitieren

APA

Kaminski, H. J., Antozzi, C., Habib, A. A., Pascuzzi, R. M., Sacconi, S., Utsugisawa, K., Vissing, J., Regnault, A., Hareendran, A., Grimson, F., Tarancón, T., Bril, V., & MycarinG study investigators (2025). Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. European Journal of Neurology, 32(8). https://doi.org/10.1111/ene.70231

Vancouver

Kaminski HJ, Antozzi C, Habib AA, Pascuzzi RM, Sacconi S, Utsugisawa K, et al. Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. European Journal of Neurology. 2025;32(8). doi:10.1111/ene.70231

BibTeX
@article{Kaminski2025,
  author = {Kaminski, Henry J and Antozzi, Carlo and Habib, Ali A and Pascuzzi, Robert M and Sacconi, Sabrina and Utsugisawa, Kimiaki and Vissing, John and Regnault, Antoine and Hareendran, Asha and Grimson, Fiona and Tarancón, Thaïs and Bril, Vera and MycarinG study investigators, MycarinG study investigators},
  title = {Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {8},
  doi = {10.1111/ene.70231}
}
Kostenlos starten →